CHINA PHARMA HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $27.76M
- P/E (TTM)
- –
- Dividend yield
- –
About China Pharma
Pharmaceutical Preparations, SIC 2834
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products, comprehensive healthcare items, and protective equipment. Operating through its subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd., the enterprise provides treatments for high-incidence and high-mortality conditions in China, including cardiovascular, central nervous system, infectious, and digestive disorders. Its offerings encompass basic generic pharmaceuticals, first-to-market generic formulations, and modern Traditional Chinese Medicines produced in formats such as tablets, capsules, injectables, and oral solutions. China Pharma distributes its prescription and healthcare products to hospitals and retail pharmacies via qualified provincial and municipal logistics distributors.
The company operates entirely within the People's Republic of China, serving medical institutions and pharmacy networks across Chinese provinces. It owns and operates two manufacturing facilities located in Haikou, Hainan Province, comprising multiple specialized buildings and production lines. China Pharma Holdings maintains its principal executive headquarters in Haikou, Hainan Province, China.
Summary of the business section of China Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CHINA PHARMA HOLDINGS, INC.
- Headquarters
- Hainan Province, F4
- Address
- 2nd Floor, No. 17, Jinpan Road, Haikou 570216
- Phone
- 8689866811730
- Employees
- 221, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Enrome LLP, Singapore
Stock & identifiers
- Ticker
- CPHI
- Exchange
- NYSE
- Shares outstanding
- 43M, Aug 11, 2026
- Public float
- $4.29M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Apr 15, 2025; 1-for-5 reverse, Apr 1, 2024; 1-for-5 reverse, Mar 6, 2024; 1-for-10 reverse, Mar 30, 2023; 1-for-10 reverse, Mar 6, 2023
- SEC CIK
- 1106644
- CUSIP
- 16941T401
- ISIN
- US16941T4013
- LEI
- 529900B3Q0CRC8OASE20
- EIN
- 73-1564807
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
China Pharma's leadership is listed in its proxy statement, last filed Nov 14, 2025.
Employees
Headcount reported in annual reports
“had 221 employees, among which 215 employees were full-time employees and 6 employees were temporary employees.”
Corporate history
Events identified from SEC filings